EA201991527A1 - EKTONUCLEOTIDASE INHIBITORS AND WAYS OF THEIR APPLICATION - Google Patents

EKTONUCLEOTIDASE INHIBITORS AND WAYS OF THEIR APPLICATION

Info

Publication number
EA201991527A1
EA201991527A1 EA201991527A EA201991527A EA201991527A1 EA 201991527 A1 EA201991527 A1 EA 201991527A1 EA 201991527 A EA201991527 A EA 201991527A EA 201991527 A EA201991527 A EA 201991527A EA 201991527 A1 EA201991527 A1 EA 201991527A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ektonucleotidase
inhibitors
ways
application
relates
Prior art date
Application number
EA201991527A
Other languages
Russian (ru)
Other versions
EA039042B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/067980 external-priority patent/WO2018119284A1/en
Publication of EA201991527A1 publication Critical patent/EA201991527A1/en
Publication of EA039042B1 publication Critical patent/EA039042B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)

Abstract

Изобретение относится к новым гетероциклическим соединениям и их фармацевтическим препаратам. Изобретение также относится к способам лечения или профилактики злокачественного новообразования с использованием новых гетероциклических соединений по изобретению.The invention relates to new heterocyclic compounds and their pharmaceutical preparations. The invention also relates to methods for the treatment or prevention of malignant neoplasm using the novel heterocyclic compounds of the invention.

EA201991527A 2017-09-08 2017-12-21 Ectonucleotidase inhibitors and methods of use thereof EA039042B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555791P 2017-09-08 2017-09-08
PCT/US2017/067980 WO2018119284A1 (en) 2016-12-22 2017-12-21 Ectonucleotidase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201991527A1 true EA201991527A1 (en) 2019-11-29
EA039042B1 EA039042B1 (en) 2021-11-25

Family

ID=68653624

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991527A EA039042B1 (en) 2017-09-08 2017-12-21 Ectonucleotidase inhibitors and methods of use thereof

Country Status (1)

Country Link
EA (1) EA039042B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
EP3134411B1 (en) * 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
EA039042B1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2019007243A (en) Ectonucleotidase inhibitors and methods of use thereof.
EA202092590A1 (en) PYRIDAZINONES AS PARP7 INHIBITORS
MX2020011528A (en) Substituted heterocyclic inhibitors of ptpn11.
EA201792231A1 (en) INDOLAMIN-2,3-DIOXYGENASE INHIBITORS AND METHODS OF THEIR APPLICATION
EA201692079A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
EA202091186A1 (en) KRas G12C INHIBITORS
EA201891494A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EA201891057A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
EA201591823A1 (en) IDO INHIBITORS
EA201690027A1 (en) IDO INHIBITORS
EA201591599A1 (en) IDO INHIBITORS
EA201690306A1 (en) IDO INHIBITORS
EA201690152A1 (en) IDO INHIBITORS
EA201790376A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA201692513A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA201891526A2 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA201790082A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMITILASE-1
EA201692480A1 (en) PHARMACEUTICAL COMPOSITION
EA201692483A1 (en) HYSTON METHYLASE INHIBITORS
EA202090572A1 (en) INHIBITORS OF RHO-ASSOCIATED SUPERSPIRAL PROTEIN KINASE
EA201992137A1 (en) Pyrimidopyrimidinones as Wee-1 Kinase Inhibitors
EA201790529A1 (en) NEW ANTIBODIES AGAINST MFI2 AND METHODS OF THEIR APPLICATION
EA201792580A1 (en) IDO INHIBITORS
EA202090306A1 (en) INHIBITORS OF RHO-ASSOCIATED CONTAINING SUPERSPIRAL PROTEINKINASE